Zenas BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zenas BioPharma, Inc. - overview
Established
2019
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Zenas BioPharma, Inc. is a biopharmaceutical company based in the U. S. focused on developing and commercializing innovative therapies for autoimmune diseases, addressing significant unmet medical needs with investigational products.
Founded in 2019 and headquartered in Waltham, US, Zenas BioPharma, Inc. specializes in advanced therapies for autoimmune diseases. The company has successfully completed 5 deals, with its most recent funding round being a PIPE of USD 5. 1 mn in September 2024, led by Fairmount Funds Management.
The firm has not undergone any significant pivots or changes in business strategy since inception. Zenas BioPharma specializes in developing and commercializing advanced therapies for autoimmune diseases, focusing on two core investigational products: obexelimab and orelabrutinib. Obexelimab is a bifunctional monoclonal antibody designed to inhibit B cell activity by targeting CD19 and FcγRIIb, addressing conditions such as Immunoglobulin G4-Related Disease (IgG4-RD), Relapsing Multiple Sclerosis (RMS), and Systemic Lupus Erythematosus (SLE). Orelabrutinib, a selective oral small molecule BTK inhibitor, targets Primary Progressive Multiple Sclerosis (PPMS) and non-active Secondary Progressive Multiple Sclerosis (naSPMS).
Zenas BioPharma serves a global client base, with a strategic focus on the U. S. and European markets for its product offerings. Zenas BioPharma's revenue model primarily revolves around partnerships and potential product commercialization.
The company engages in strategic collaborations with healthcare organizations and leverages licensing agreements to expand its market reach. While specific pricing plans for obexelimab and orelabrutinib have not been disclosed, the revenue for the most recent year (2025) is reported at USD 10. 00 mn, with an EBITDA of USD -384. 93 mn.
The revenue stream is anticipated to grow once these products gain regulatory approval and enter the market. Zenas BioPharma plans to leverage the proceeds from its recent IPO, which raised USD 209. 00 mn, to advance its clinical trials and prepare for product launches. The company is targeting expansion into key markets in Europe and North America by 2025.
The successful commercialization of obexelimab and orelabrutinib is expected to play a pivotal role in Zenas's growth strategy as it aims to meet the needs of patients with autoimmune diseases.
Current Investors
Fairmount Funds Management, Vivo Capital, Wellington Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.zenasbio.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Zenas BioPharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Zenas BioPharma, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.